{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:07:23Z","timestamp":1790719643653,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40266-013-0144-2","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T04:58:53Z","timestamp":1386824333000},"page":"11-20","source":"Crossref","is-referenced-by-count":42,"title":["Adverse Effects of Clozapine in Older Patients: Epidemiology, Prevention and Management"],"prefix":"10.1007","volume":"31","author":[{"given":"Delia","family":"Bishara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"144_CR1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/YIC.0b013e32834405fc","volume":"26","author":"J Snowdon","year":"2011","unstructured":"Snowdon J, Halliday G. A study of the use of clozapine in old age psychiatry. Int Clin Psychopharmacol. 2011;26:232\u20135.","journal-title":"Int Clin Psychopharmacol"},{"key":"144_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789\u201396.","journal-title":"Arch Gen Psychiatry"},{"key":"144_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/appi.ps.51.5.669","volume":"51","author":"M Sajatovic","year":"2000","unstructured":"Sajatovic M, Bingham CR, Garver D, et al. An assessment of clinical practice of clozapine therapy for veterans. Psychiatr Serv. 2000;51:669\u201371.","journal-title":"Psychiatr Serv"},{"key":"144_CR4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1988.tb01785.x","volume":"36","author":"L Nolan","year":"1988","unstructured":"Nolan L, O\u2019Malley K. Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36:142\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"144_CR5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0895-4356(97)00306-5","volume":"51","author":"M van den Akker","year":"1998","unstructured":"van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998;51:367\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 8","key":"144_CR6","first-page":"29","volume":"60","author":"SM Maixner","year":"1999","unstructured":"Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry. 1999;60(Suppl 8):29\u201341.","journal-title":"J Clin Psychiatry"},{"key":"144_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","volume":"158","author":"JA Lieberman","year":"1991","unstructured":"Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503\u201310.","journal-title":"Br J Psychiatry"},{"key":"144_CR8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","volume":"7","author":"P Gareri","year":"2008","unstructured":"Gareri P, De Fazio P, Russo E, et al. The safety of clozapine in the elderly. Expert Opin Drug Saf. 2008;7:525\u201338.","journal-title":"Expert Opin Drug Saf"},{"key":"144_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00131746-200509000-00003","volume":"11","author":"AY Khan","year":"2005","unstructured":"Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract. 2005;11:289\u2013301.","journal-title":"J Psychiatr Pract"},{"key":"144_CR10","first-page":"47","volume":"55 Suppl B","author":"HY Meltzer","year":"1994","unstructured":"Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55 Suppl B:47\u201352.","journal-title":"J Clin Psychiatry"},{"key":"144_CR11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-005-0248-4","volume":"185","author":"SK Praharaj","year":"2006","unstructured":"Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185:265\u201373.","journal-title":"Psychopharmacology"},{"key":"144_CR12","first-page":"180","volume":"56","author":"JK Pitner","year":"1995","unstructured":"Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry. 1995;56:180\u20135.","journal-title":"J Clin Psychiatry"},{"key":"144_CR13","first-page":"12","volume":"8","author":"KN Chengappa","year":"1995","unstructured":"Chengappa KN, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol. 1995;8:12\u20135.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"144_CR14","first-page":"113","volume":"33","author":"RW Shulman","year":"1997","unstructured":"Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull. 1997;33:113\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"144_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00002512-200522010-00003","volume":"22","author":"M Sajatovic","year":"2005","unstructured":"Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005;22:39\u201354.","journal-title":"Drugs Aging"},{"key":"144_CR16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"The Parkinson Study Group","year":"1999","unstructured":"The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"144_CR17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","volume":"17","author":"H Frieling","year":"2007","unstructured":"Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson\u2019s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165\u201371.","journal-title":"Eur Neuropsychopharmacol"},{"key":"144_CR18","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146\u201356.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"144_CR19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843\u201353.","journal-title":"Exp Gerontol"},{"key":"144_CR20","unstructured":"Novartis Pharmaceuticals UK Limited. Summary of product characteristics [pamphlet]. Clozaril 25\u00a0mg and 100\u00a0mg tablets; 2013. http:\/\/www.medicines.org.uk\/emc\/medicine\/1277\/SPC\/Clozaril+25mg+and+100mg+Tablets\/ . Accessed 3 Dec 2013."},{"key":"144_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/SMJ.0b013e31825fed90","volume":"105","author":"JM Wooten","year":"2012","unstructured":"Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012;105:437\u201345.","journal-title":"South Med J"},{"key":"144_CR22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329:162\u20137.","journal-title":"N Engl J Med"},{"key":"144_CR23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00048679709073852","volume":"31","author":"L Herst","year":"1997","unstructured":"Herst L, Powell G. Is clozapine safe in the elderly? Aust N\u00a0Z J Psychiatry. 1997;31:411\u20137.","journal-title":"Aust N\u00a0Z J Psychiatry"},{"key":"144_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-199812020-00004","volume":"12","author":"RA Sweet","year":"1998","unstructured":"Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging. 1998;12:115\u201327.","journal-title":"Drugs Aging"},{"key":"144_CR25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","volume":"24","author":"CR Young","year":"1998","unstructured":"Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24:381\u201390.","journal-title":"Schizophr Bull"},{"key":"144_CR26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","volume":"134","author":"P Manu","year":"2012","unstructured":"Manu P, Sarpal D, Muir O, et al. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012;134:180\u20136.","journal-title":"Schizophr Res"},{"key":"144_CR27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/0897190007304982","volume":"20","author":"M Malone","year":"2007","unstructured":"Malone M, Carnahan RM, Kutscher EC. Antipsychotic medication use in the elderly patient. J Pharm Pract. 2007;20:318\u201326.","journal-title":"J Pharm Pract"},{"key":"144_CR28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","volume":"45","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N\u00a0Z J Psychiatry. 2011;45:458\u201365.","journal-title":"Aust N\u00a0Z J Psychiatry"},{"key":"144_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2004.00616_1.x","volume":"30","author":"PM Wehmeier","year":"2005","unstructured":"Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther. 2005;30:91\u20136.","journal-title":"J Clin Pharm Ther"},{"key":"144_CR30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.genhosppsych.2007.09.003","volume":"30","author":"C Rostagno","year":"2008","unstructured":"Rostagno C, Di NG, Placidi GF, et al. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry. 2008;30:280\u20133.","journal-title":"Gen Hosp Psychiatry"},{"key":"144_CR31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00002512-200118010-00004","volume":"18","author":"MJ Byerly","year":"2001","unstructured":"Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging. 2001;18:45\u201361.","journal-title":"Drugs Aging"},{"key":"144_CR32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","unstructured":"The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet. 1999;353:2041\u20132.","journal-title":"Lancet"},{"key":"144_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.8.1.1","volume":"8","author":"WS Musser","year":"1996","unstructured":"Musser WS, Akil M. Clozapine as a treatment for psychosis in Parkinson\u2019s disease: a review. J Neuropsychiatry Clin Neurosci. 1996;8:1\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"144_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/jnp.10.2.227","volume":"10","author":"WJ Burke","year":"1998","unstructured":"Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 1998;10:227\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"144_CR35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/JCP.0b013e3181e69060","volume":"30","author":"TK Rajji","year":"2010","unstructured":"Rajji TK, Uchida H, Ismail Z, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol. 2010;30:431\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"144_CR36","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.npp.1300768","volume":"30","author":"Z Li","year":"2005","unstructured":"Li Z, Huang M, Ichikawa J, et al. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology. 2005;30:1986\u201395.","journal-title":"Neuropsychopharmacology"},{"key":"144_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/10398560701882203","volume":"16","author":"S Rege","year":"2008","unstructured":"Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Austral Psychiatry. 2008;16:216\u20139.","journal-title":"Austral Psychiatry"},{"key":"144_CR38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","volume":"69","author":"SE Palmer","year":"2008","unstructured":"Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69:759\u201368.","journal-title":"J Clin Psychiatry"},{"key":"144_CR39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4088\/JCP.v66n0514","volume":"66","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson\u2019s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633\u20137.","journal-title":"J Clin Psychiatry"},{"key":"144_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/089198879400700209","volume":"7","author":"FR Frankenburg","year":"1994","unstructured":"Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol. 1994;7:129\u201332.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"144_CR41","first-page":"38","volume":"59","author":"JA Lieberman","year":"1998","unstructured":"Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry. 1998;59:38\u201343.","journal-title":"J Clin Psychiatry"},{"key":"144_CR42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/WNF.0b013e3181a620b2","volume":"32","author":"R Stryjer","year":"2009","unstructured":"Stryjer R, Timinsky I, Reznik I, et al. Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol. 2009;32:290\u20132.","journal-title":"Clin Neuropharmacol"},{"key":"144_CR43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-200108000-00005","volume":"21","author":"S Hagg","year":"2001","unstructured":"Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21:382\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"144_CR44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00002512-199507030-00004","volume":"7","author":"CA Naranjo","year":"1995","unstructured":"Naranjo CA, Herrmann N, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging. 1995;7:184\u2013202.","journal-title":"Drugs Aging"},{"key":"144_CR45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","volume":"1","author":"S Varma","year":"2011","unstructured":"Varma S, Bishara D, Besag FMC, et al. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011;1:47\u201366.","journal-title":"Ther Adv Psychopharmacol"},{"key":"144_CR46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gps.930070912","volume":"7","author":"CJ Ball","year":"1992","unstructured":"Ball CJ. The use of clozapine in older people. Int J Geriatr Psychiatry. 1992;7:689\u201392.","journal-title":"Int J Geriatr Psychiatry"},{"key":"144_CR47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF01064682","volume":"63","author":"JA Lieberman","year":"1992","unstructured":"Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63:51\u201370.","journal-title":"Psychiatr Q"},{"key":"144_CR48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/089719009600900208","volume":"9","author":"DM Guith","year":"1996","unstructured":"Guith DM. Clozapine: serious adverse side effects, drug interactions, and other complications of therapy. J Pharm Pract. 1996;9:118\u201329.","journal-title":"J Pharm Pract"},{"key":"144_CR49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","volume":"15","author":"MM Iqbal","year":"2003","unstructured":"Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33\u201348.","journal-title":"Ann Clin Psychiatry"},{"key":"144_CR50","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1345\/aph.19259","volume":"34","author":"L Davydov","year":"2000","unstructured":"Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother. 2000;34:662\u20135.","journal-title":"Ann Pharmacother"},{"key":"144_CR51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/070674370705200607","volume":"52","author":"S Sockalingam","year":"2007","unstructured":"Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry. 2007;52:377\u201384.","journal-title":"Can J Psychiatry"},{"key":"144_CR52","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.08m04495","volume":"70","author":"S Sockalingam","year":"2009","unstructured":"Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2009;70:1114\u20139.","journal-title":"J Clin Psychiatry"},{"key":"144_CR53","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(95)91713-6","volume":"346","author":"J Fritze","year":"1995","unstructured":"Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation. Lancet. 1995;346:1034.","journal-title":"Lancet"},{"key":"144_CR54","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00004714-200112000-00012","volume":"21","author":"YM Bai","year":"2001","unstructured":"Bai YM, Lin CC, Chen JY, et al. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol. 2001;21:608\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"144_CR55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2004-815523","volume":"37","author":"B Schneider","year":"2004","unstructured":"Schneider B, Weigmann H, Hiemke C, et al. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry. 2004;37:43\u20135.","journal-title":"Pharmacopsychiatry"},{"key":"144_CR56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v57n1102","volume":"57","author":"MA Fuller","year":"1996","unstructured":"Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry. 1996;57:514\u20138.","journal-title":"J Clin Psychiatry"},{"key":"144_CR57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/j.1440-1614.2005.01705_4.x","volume":"39","author":"S Sarma","year":"2005","unstructured":"Sarma S, Ward W, O\u2019Brien J, et al. Severe hyponatraemia associated with desmopressin nasal spray to treat clozapine-induced nocturnal enuresis. Aust N Z J Psychiatry. 2005;39:949.","journal-title":"Aust N Z J Psychiatry"},{"key":"144_CR58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/10398560903254193","volume":"18","author":"G Malhi","year":"2010","unstructured":"Malhi G, Adams D, Plain J, et al. Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context. Austral Psychiatry. 2010;18:32\u201341.","journal-title":"Austral Psychiatry"},{"key":"144_CR59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","volume":"157","author":"DC Henderson","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975\u201381.","journal-title":"Am J Psychiatry"},{"key":"144_CR60","first-page":"399","volume":"38","author":"R Holt","year":"2008","unstructured":"Holt R. The metabolic side-effects of antipsychotics in elderly patients. Geriatr Med. 2008;38:399\u2013402.","journal-title":"Geriatr Med"},{"key":"144_CR61","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1073\/pnas.0700090104","volume":"104","author":"HY Meltzer","year":"2007","unstructured":"Meltzer HY. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proc Natl Acad Sci U\u00a0S\u00a0A. 2007;104:3019\u201320.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"144_CR62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","volume":"64","author":"K Melkersson","year":"2004","unstructured":"Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701\u201323.","journal-title":"Drugs"},{"key":"144_CR63","volume-title":"Maudsley prescribing guidelines in psychiatry","author":"D Taylor","year":"2012","unstructured":"Taylor D, Paton C, Kapur S. Maudsley prescribing guidelines in psychiatry. 11th ed. Oxford: Wiley-Blackwell; 2012.","edition":"11"},{"key":"144_CR64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/hup.2223","volume":"27","author":"S Bowskill","year":"2012","unstructured":"Bowskill S, Couchman L, MacCabe JH, et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65\u00a0years and over: data from a therapeutic drug monitoring service, 1996\u20132010. Hum Psychopharmacol. 2012;27:277\u201383.","journal-title":"Hum Psychopharmacol"},{"key":"144_CR65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/JGP.0b013e3182118318","volume":"20","author":"Z Ismail","year":"2012","unstructured":"Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53\u201360.","journal-title":"Am J Geriatr Psychiatry"},{"key":"144_CR66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2125.2007.02852.x","volume":"64","author":"YL Tang","year":"2007","unstructured":"Tang YL, Mao P, Li FM, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol. 2007;64:49\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"144_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-200505000-00007","volume":"20","author":"CH Ng","year":"2005","unstructured":"Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20:163\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"144_CR68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","volume":"24","author":"A Rostami-Hodjegan","year":"2004","unstructured":"Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"144_CR69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","volume":"100","author":"E Spina","year":"2007","unstructured":"Spina E, de LJ. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4\u201322.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"144_CR70","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<553::AID-GPS547>3.0.CO;2-U","volume":"12","author":"M Sajatovic","year":"1997","unstructured":"Sajatovic M, Jaskiw G, Konicki PE, et al. Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry. 1997;12:553\u20138.","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0144-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0144-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0144-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T16:47:18Z","timestamp":1564937238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0144-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0144-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,13]]}}}